

**Claims**

1. A method of treating a human body for cancer comprising administering an effective therapeutic amount of doxorubicin, in combination with ET-743 in a dose range between 0.5 and 1 mg/m<sup>2</sup> for ET-743.
2. A method of treating a human body for cancer comprising administering an effective therapeutic amount of ET-743, in combination with doxorubicin in a dose range between 40 and 80 mg/m<sup>2</sup> for doxorubicin.
3. The method according to claim 1 or 2, wherein doxorubicin and ET-743 are provided as separate medicaments for administration at different times.
4. The method according to claim 3, wherein doxorubicin is administered prior to the administration of ET-743.
5. The method according to claim 4, wherein doxorubicin and ET-743 are administered by intravenous injection.
6. The method according to claim 5, wherein the infusion time for intravenous injection is up to 3 hours for doxorubicin and up to 24 hours for ET-743.
7. The method according to claim 6, wherein the infusion time for intravenous injection is about 1 hour for doxorubicin and about 3 hours for ET-743.
8. The method according to claim 7, where the infusions are carried out at an interval of 1 to 6 weeks.

9. The method according to claim 8, wherein the infusions of both drugs are carried out once every 21 days.
10. The method according to claim 8, wherein the infusion of doxorubicin is carried out on day 1 and the infusion of ET-743 on days 1 and 8, every 21 days.
11. The method according to claim 9 or 10, wherein doxorubicin is administered in a dosage of up to 60 mg/m<sup>2</sup>, followed by ET-743 which is administered in a dosage of up to 0.7 mg/m<sup>2</sup>.
12. The method according to claim 11, wherein doxorubicin is administered in a dosage about 60 mg/m<sup>2</sup>, followed by ET-743 which is administered in a dosage about 0.7 mg/m<sup>2</sup>.
13. The method according to claim 11, wherein doxorubicin is administered in a dosage about 50 mg/m<sup>2</sup>, followed by ET-743 which is administered in a dosage about 0.6 mg/m<sup>2</sup>.
14. A method according to any preceding claim, in which the patient has a cancer selected from sarcoma, osteosarcoma, ovarian cancer, breast cancer, melanoma, colorectal cancer, mesothelioma, renal cancer, endometrial cancer and lung cancer.
15. A method according to claim 14, in which the patient has a cancer selected from sarcoma, ovarian cancer, endometrial cancer and breast cancer.
16. The use of doxorubicin in the preparation of a medicament for a method according to any of claims 1 to 15.
17. The use of ET-743 in the preparation of a medicament for a method according to any of claims 1 to 15.

18. A medical kit for administering ET-743 in combination with doxorubicin, comprising a supply of ET-743 in dosage units for at least one cycle, wherein each dosage unit contains the appropriate amount of ET-743 for the treatments and a pharmaceutically acceptable carrier, and printed instructions for administering ET-743 according to a dosing schedule.